ClinicalTrials.gg
RecruitingNCT07658560Updated Oct 15, 2026

A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes

A Phase 2 interventional study of BGM0504 tablets and BGM0504 tablets in Overweight or Obese Participants Without Diabetes, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 15, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 330 studies in Overweight with a site in China — 123 open to participants now, 166 under way, 43 of them phase 3. Overweight · China.

Planned enrollment
99th of 296
200 · median 120
Started
2026
with 97 others
Phase 2
37 of 330
11 open now
Primary completion
2027-02
later than 77 of 165 live
Registered
264th of 330
by date
Lead sponsor
7 of 330
BrightGene Bio-Medical Technology Co., Ltd.

Among the 330 studies in Overweight with a site in China, this one is the 99th largest by planned enrollment of the 296 interventional ones that give a count, is one of 98 that started in 2026, is one of 37 in phase 2, reaches primary completion later than 77 of the 165 other live ones, and was the 264th registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

123 of the 330 studies in Overweight with a site in China are open now. Recruiting first, the newest first:

117 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 330 studies in Overweight with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy of BGM0504 tablets compared with placebo in reducing body weight in overweight or obese participants without diabetes after 20 weeks of treatment.

03

Conditions studied

  • Overweight or Obese Participants Without Diabetes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ○ Participants must be Chinese, non-diabetic, overweight or obese individuals aged 18 to 55 years (inclusive), as determined by the time of signing the form. Both men and women are eligible.

    • (Medical history and examination) Obese participants: ≥ 28.0 kg/m²; or overweight participants: 24.0 kg/m² ≤ BMI \< 28.0 kg/m² and have at least one of the following conditions: i. Pre-diabetes (impaired fasting glucose and/or impaired glucose tolerance), hypertension, non-alcoholic fatty liver disease, or dyslipidemia; ii. Weight-bearing joint pain; iii. Obesity-induced breathing difficulties or obstructive sleep apnea syndrome.
    • (Medical history) Participants must have undergone at least 12 weeks of diet and exercise control before screening, with a weight change of less than 5.0% (self-reported), and be willing to continue with the same diet and exercise control during the trial period.
    • For participants with hypertension at screening, the sitting systolic blood pressure (sitSBP) and sitting diastolic blood pressure (sitDBP) at the time of enrollment must be sitSBP \< 160 mmHg and sitDBP \< 100 mmHg. They must be on stable treatment with two or fewer antihypertensive drugs (monotherapy, combination of two drugs, or fixed-dose combination) for at least two weeks or have been on diet and exercise control without antihypertensive drugs for at least four weeks.
    • Participants must be willing to take effective measures from the time of signing the informed consent form until one month after the last dose and have no plans to donate sperm or eggs.
    • Participants must commit to having no history of mental disorders, be able to communicate smoothly with the researchers, fully understand the trial content, process, and potential adverse reactions, strictly follow the research procedures, and voluntarily participate by signing the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • ● (Medical Inquiry) Individuals with a history of severe drug allergy (especially known or suspected allergy to the components and of BGM0504 tablets) or with a severe specific allergic reaction disease/condition (such as asthma, urticaria, eczema, etc.) or with a severe allergic constitution (two or more food or drug allergies);

    • (Medical Inquiry) Before screening, they used any of the following drugs or treatments:

      1. Within the previous 12 weeks, used GLP-1 receptor agonists or similar drugs targeting the same target, including semaglutide, liraglutide, dulaglutide, exenatide, lisaglutide, benralizumab, lorcetanib, enoglutide, etc. of the GLP-1RA class; telprotide, etc. of the GLP-1/GIP, Masudopeptide GLP-1/GCG, dual-target agonists; other drugs containing GLP-1 and other related weight loss targets in the experimental stage;
      2. Within the previous 12 weeks, used systemic , including short-acting ones such as hydrocortisone, cortisone; medium-acting ones such as prednisone, prednisolone, methylprednisolone, triamcinolone; long-acting ones such as dexamethasone, betamethasone;
      3. Within the previous 12 weeks, used tricyclic antidepressants, psychiatric drugs or sedatives that significantly affect body weight, including imipramine, amitriptyline, mirtazapine, paroxetine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, lithium salts, etc.;
      4. Within the previous 12 weeks, used drugs for weight control, such as: sibutramine, phenbutyram, phenylpropanolamine, chlorbiménoxide, fenfluramine, aniracetam, chlorcardinol, fenfluramine/trospirenone combination, naltrexone/anhydrotoban combination, orlistat, etc.;
      5. Within the previous 12 weeks, used other drugs or supplements for weight loss purposes, or meal replacement products, including other prescription drugs, over-the-counter drugs, Chinese herbal medicines, supplements, meal replacement products (whether for weight loss purposes is determined by the prescription or product instructions);
      6. Non-pharmaceutical treatments such as acupuncture and physical therapy for the purpose of weight loss were received within 12 weeks before screening (whether it is for the purpose of weight loss is subject to the medical record or prescription);
    • (Examination) At the screening/baseline stage, any one of the following laboratory test indicators meets the following criteria:

      1. (HbA1c) ≥6.5%, fasting blood glucose ≥7.0 mmol/L, or 2-hour blood glucose of oral glucose tolerance test (OGTT) ≥11.1 mmol/L (during screening, participants with fasting blood glucose ranging from 6.1 to 6.9 mmol/L need to undergo the OGTT test);
      2. or AST ≥ 2.5 times the (ULN), or total ≥ 1.5 times the ULN;
      3. (eGFR) ≤ 60 mL/min/1.73m2 (CKD-EPI formula);
      4. Serum calcitonin level ≥ 35 ng/L (pg/mL);
      5. Thyroid stimulating hormone (TSH) > 6.0 mIU/L or \< 0.4 mIU/L;
      6. Fasting triglycerides ≥ 5.64 mmol/L (500 mg/dL);
      7. (HGB) \< 100 g/L;
      8. Serum amylase or serum lipase > 2.0 × ULN;
      9. Positive surface antigen (HBsAg) and abnormal hepatitis B virus load (HBV-DNA) test value;
      10. Positive antibody (HCV-Ab) and abnormal hepatitis C virus load (HCV-RNA) test value;
      11. Positive immunodeficiency virus antibody (-Ab) or positive syphilis spirochete antibody (TPAb).
    • During the screening/baseline assessment, 12-lead showed a heart rate of less than 50 beats per minute or more than 100 beats per minute, second or third degree atrioventricular block, long syndrome or female QTcF greater than 470 ms or male greater than 450 ms, or other electrocardiogram abnormalities judged by the researchers as requiring drug intervention;
    • There is a history or evidence of any of the following diseases:

      1. (Interview) It belongs to a secondary disease or drug-induced obesity, including: elevated cortisol hormone (such as Cushing's syndrome), obesity caused by damage to the pituitary and hypothalamus, obesity caused by reducing or discontinuing weight loss drugs, etc.;
      2. (Interview/Examination) Previously or during screening diagnosed with type 1 or type 2 diabetes;
      3. (Interview) Previously diagnosed with acute or chronic pancreatitis, or pancreatic injury;
      4. (Interview) Previously diagnosed with thyroid C-cell carcinoma, MEN (multiple endocrine neoplasia) type 2A or 2B, or having a related family history;
      5. (Interview) Previously undergone gastric weight loss surgery, or within 1 year before screening underwent liposuction or fat removal surgery, or planned to undergo weight loss surgery, liposuction or abdominal fat removal surgery during the study period, which significantly affects body weight;
      6. (Interview) Previously had a moderate or severe depression history, or during screening the PHQ-9 (depression screening scale) questionnaire was ≥ 15 points, or had a history of other serious mental illness, or had suicidal tendencies or suicidal behavior;
      7. (Interview) Confirmed to have a malignant tumor within 5 years before screening (cured carcinoma in situ can be excluded);
      8. (Interview/Examination) Had any of the following heart diseases within 6 months before screening: such as decompensated heart function insufficiency ( classification of grade III or IV); unstable angina pectoris, myocardial infarction, history of coronary artery bypass grafting or coronary stent implantation;
      9. (Interview) Had hemorrhagic stroke or ischemic stroke within 6 months before screening, and the researcher evaluated that it was not suitable to participate in this clinical trial;
      10. (Interview) Had severe hypoglycemia or recurrent (≥ 2 times within 6 months) symptomatic hypoglycemia within 6 months before screening;
      11. (Examination) Had thyroid dysfunction that could not be controlled with stable drug doses, or the thyroid function test results had abnormalities and required initiation of treatment during screening;
      12. (Interview/Examination) Abdominal B-ultrasound at screening indicated the presence of gallbladder stones, clinical symptoms or treatment-requiring gallbladder polyps, or other clinical symptoms of gallbladder diseases;
      13. (Interview) Had significant gastric emptying abnormalities at screening (such as severe gastroparesis or gastric outlet obstruction), or currently had severe gastrointestinal diseases affecting drug absorption, distribution, metabolism, and excretion, or had undergone gastrointestinal surgery affecting drug absorption (such as gastrointestinal anastomosis or intestinal resection);
    • (Interview) Suspected or confirmed to have a history of drug abuse or alcohol abuse during screening;
    • (Interview/Query) Participants who had participated in drug or medical device clinical trials within 3 months before screening and received the study drug (placebo excluded) or medical device intervention;
    • (Interview) Participants who had donated blood or lost blood ≥ 400 mL (except for blood loss during menstruation) within 3 months before screening or planned to donate blood during the trial or after the trial;
    • (Interview/Examination) Pregnant or lactating female trial participants;
    • Other trial participants determined by the researcher to be unsuitable to participate in this study or who withdrew from the trial for personal reasons.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    The dose1 group

    Administered p.o once daily,tablets

    Drug: BGM0504 tablets

  • Experimental
    The dose2 group

    Administered p.o once daily,tablets

    Drug: BGM0504 tablets

  • Experimental
    The dose3 group

    Administered p.o once daily,tablets

    Drug: BGM0504 tablets

  • Experimental
    The dose4 group

    Administered p.o once daily,tablets

    Drug: BGM0504 tablets

  • Placebo comparator
    Placebo group

    Administered p.o once daily,tablets

    Drug: BGM0504 placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Fasting body weight

    Time frame: 20 weeks

Secondary outcomes

  1. Pharmacodynamics (PD)endpoint:waist circumference

    Time frame: 4、8、12、16、20 weeks

  2. PD endpoint:Body Mass Index(BMI)

    Time frame: 4、8、12、16、20 weeks

  3. PD endpoint:fasting insulin

    Time frame: 4、8、12、16、20 weeks

  4. PD endpoint: fasting blood glucose

    Time frame: 4、8、12、16、20 weeks

  5. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: Baseline

  6. 12-lead electrocardiogram (ECG), including heart rate, PR interval, QRS duration, QT interval, QTc interval, and QTcF

    Time frame: Baseline

  7. Number of participants who are pregnant

    Time frame: Baseline

  8. Number of Participants with Hypoglycemic Events

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Feb 2027, 7 months after the start.

Of 102 industry-sponsored phase 2 interventional studies under Overweight, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 16. This study's planned 7 months is below that.

Counting every sponsor, half of 148 studies reached it within 13 months; a quarter within 8 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jun 22, 2026
StartActual
Jun 29, 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
Peking University People's Hospital is now Recruiting
Oct 15, 2026
Start date
Jun 30, 2026→Jun 29, 2026 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    Peking University People's Hospital is now Recruiting
    Start date Jun 30, 2026→Jun 29, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07658560
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jun 29, 2026
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Linong Ji
Contact
jiln@bjmu.edu.cn
(+86) 13910978815

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BGM0504

Start the discussion